Corium International Company Profile (NASDAQ:CORI)

About Corium International

Corium International logoCorium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CORI
  • CUSIP:
Key Metrics:
  • Previous Close: $3.51
  • 50 Day Moving Average: $3.61
  • 200 Day Moving Average: $4.81
  • 52-Week Range: $29,224,000.00 - $2.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.61
  • P/E Growth: 0.00
  • Market Cap: $112.22M
  • Outstanding Shares: 29,224,000
  • Beta: 1.07
Profitability:
  • Net Margins: -116.26%
  • Return on Equity: -359.24%
  • Return on Assets: -50.22%
Debt:
  • Debt-to-Equity Ratio: 17.88%
  • Current Ratio: 6.06%
  • Quick Ratio: 5.75%
Additional Links:
Companies Related to Corium International:

Analyst Ratings

Consensus Ratings for Corium International (NASDAQ:CORI) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.17 (190.80% upside)

Analysts' Ratings History for Corium International (NASDAQ:CORI)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017Jefferies Group LLCLower Price TargetBuy$9.00 -> $8.00View Rating Details
2/14/2017Cantor FitzgeraldSet Price TargetBuy$10.00View Rating Details
2/14/2017FBR & CoSet Price TargetBuy$12.00View Rating Details
2/14/2017Needham & Company LLCLower Price TargetBuy$12.00 -> $10.00View Rating Details
1/4/2017Leerink SwannReiterated RatingBuyView Rating Details
5/3/2016WBB SecuritiesUpgradeHold -> Speculative Buy$11.00View Rating Details
6/9/2015GuggenheimInitiated CoverageBuy$18.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Corium International (NASDAQ:CORI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
2/13/2017Q1 2017($0.42)($0.46)$8.07 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q2($0.37)($0.47)ViewListenView Earnings Details
2/8/2016Q1($0.35)($0.42)ViewN/AView Earnings Details
11/12/2015Q4($0.45)($0.42)ViewListenView Earnings Details
2/10/2015Q115($0.24)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details
11/17/2014($0.32)($0.51)ViewN/AView Earnings Details
8/12/2014($0.17)($0.28)ViewN/AView Earnings Details
5/14/2014($0.18)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corium International (NASDAQ:CORI)
Current Year EPS Consensus Estimate: $-1.62 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.38)($0.38)($0.38)
Q2 20161($0.35)($0.35)($0.35)
Q3 20163($0.43)($0.41)($0.42)
Q4 20163($0.46)($0.30)($0.38)
Q1 20173($0.50)($0.39)($0.43)
Q2 20173($0.44)($0.36)($0.39)
Q3 20173($0.41)($0.24)($0.34)
Q4 20173($0.45)($0.27)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Corium International (NASDAQ:CORI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Corium International (NASDAQ:CORI)
Insider Ownership Percentage: 45.70%
Institutional Ownership Percentage: 67.75%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.00View SEC Filing  
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Corium International (NASDAQ:CORI)
DateHeadline
4-traders.com logoCorium International,Inc. (NASDAQ:CORI) Files An 8-K Results of Operations and Financial Condition (NASDAQ:CORI)
www.4-traders.com - February 14 at 10:16 PM
biz.yahoo.com logoCORIUM INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CORI)
biz.yahoo.com - February 14 at 5:14 PM
finance.yahoo.com logoEdited Transcript of CORI earnings conference call or presentation 13-Feb-17 10:00pm GMT (NASDAQ:CORI)
finance.yahoo.com - February 14 at 5:14 PM
4-traders.com logoCORIUM INTERNATIONAL, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:CORI)
www.4-traders.com - February 13 at 10:08 PM
sg.finance.yahoo.com logoCorium reports 1Q loss (NASDAQ:CORI)
sg.finance.yahoo.com - February 13 at 10:08 PM
biz.yahoo.com logoQ1 2017 Corium International Inc Earnings Release - After Market Close (NASDAQ:CORI)
us.rd.yahoo.com - February 13 at 5:06 PM
us.rd.yahoo.com logoCorium Reports First Quarter Fiscal 2017 Financial Results (NASDAQ:CORI)
us.rd.yahoo.com - February 13 at 5:06 PM
finance.yahoo.com logoCorium to Present at Upcoming Investor Conferences (NASDAQ:CORI)
finance.yahoo.com - February 7 at 5:33 PM
finance.yahoo.com logoCorium to Report First Quarter Fiscal Year 2017 Financial Results on Monday, February 13, 2017 (NASDAQ:CORI)
finance.yahoo.com - February 6 at 4:29 PM
streetinsider.com logoCorium Internation (CORI) Plans Offering of Common Stock (NASDAQ:CORI)
www.streetinsider.com - February 3 at 4:44 PM
4-traders.com logoCORIUM INTERNATIONAL, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:CORI)
www.4-traders.com - February 3 at 4:44 PM
us.rd.yahoo.com logoCorium Prices Follow-On Offering of Common Stock (NASDAQ:CORI)
us.rd.yahoo.com - February 2 at 4:50 PM
us.rd.yahoo.com logo4:24 pm Corium International intends to offer shares of its common stock in an underwritten public offering; size not disclosed (NASDAQ:CORI)
us.rd.yahoo.com - February 2 at 2:45 AM
einnews.com logoAir Force general stripped of 2 stars due to sex misconduct (NASDAQ:CORI)
uspolitics.einnews.com - February 1 at 9:44 PM
einnews.com logoFacebook Inc ordered by jury to pay US$500 million for using stolen tech in its Oculus VR headset (NASDAQ:CORI)
brazilbusiness.einnews.com - February 1 at 9:44 PM
finance.yahoo.com logoCorium Announces Proposed Public Offering of Common Stock (NASDAQ:CORI)
finance.yahoo.com - February 1 at 4:43 PM
News IconCorium International Inc CORI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CORI)
www.bioportfolio.com - January 27 at 10:51 PM
reuters.com logoBRIEF-Corium International says enters extended agreement with P&G (NASDAQ:CORI)
www.reuters.com - January 20 at 5:39 PM
biz.yahoo.com logoCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:CORI)
biz.yahoo.com - January 20 at 5:39 PM
marketexclusive.com logoCorium International,Inc. (NASDAQ:CORI) Files An 8-K Regulation FD Disclosure (NASDAQ:CORI)
marketexclusive.com - January 9 at 5:34 PM
biz.yahoo.com logoCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CORI)
biz.yahoo.com - January 9 at 5:34 PM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Reiterates Buy on Corium International (NASDAQ:CORI) (NASDAQ:CORI)
marketexclusive.com - January 6 at 9:54 PM
capitalcube.com logoETFs with exposure to Corium International, Inc. : January 6, 2017 (NASDAQ:CORI)
www.capitalcube.com - January 6 at 4:52 PM
capitalcube.com logoCorium International, Inc. :CORI-US: Earnings Analysis: 2016 By the Numbers : December 23, 2016 (NASDAQ:CORI)
www.capitalcube.com - December 23 at 4:39 PM
capitalcube.com logoETFs with exposure to Corium International, Inc. : December 23, 2016 (NASDAQ:CORI)
www.capitalcube.com - December 23 at 4:39 PM
biz.yahoo.com logoCORIUM INTERNATIONAL, INC. Files SEC form 10-K, Annual Report (NASDAQ:CORI)
biz.yahoo.com - December 20 at 5:06 PM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Initiates Coverage On Corium International (NASDAQ:CORI) With a Overweight (NASDAQ:CORI)
marketexclusive.com - December 17 at 9:42 PM
capitalcube.com logoETFs with exposure to Corium International, Inc. : December 9, 2016 (NASDAQ:CORI)
www.capitalcube.com - December 9 at 4:43 PM
News IconAequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues (NASDAQ:CORI)
www.bctechnology.com - December 5 at 12:24 PM
News IconCorium International, Inc. CORI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CORI)
www.bioportfolio.com - December 5 at 12:24 PM
capitalcube.com logoCorium International, Inc. :CORI-US: Earnings Analysis: Q4, 2016 By the Numbers : November 28, 2016 (NASDAQ:CORI)
www.capitalcube.com - November 30 at 9:37 AM
fxpips.com logoNASDAQ Trading – Most Declined Company Stocks (NASDAQ:CORI)
www.fxpips.com - November 22 at 8:13 AM
finance.yahoo.com logoEdited Transcript of CORI earnings conference call or presentation 21-Nov-16 10:00pm GMT (NASDAQ:CORI)
finance.yahoo.com - November 22 at 8:13 AM
sg.finance.yahoo.com logoCorium reports 4Q loss (NASDAQ:CORI)
sg.finance.yahoo.com - November 21 at 10:23 PM
News IconCorium International, Inc. CORI Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:CORI)
www.bioportfolio.com - November 21 at 4:37 PM
publicnow.com logoCorium Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Highlights (NASDAQ:CORI)
www.publicnow.com - November 21 at 4:37 PM
biz.yahoo.com logoCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:CORI)
biz.yahoo.com - November 21 at 4:37 PM
biz.yahoo.com logoQ4 2016 Corium International Inc Earnings Release - After Market Close (NASDAQ:CORI)
biz.yahoo.com - November 21 at 9:20 AM
fxpips.com logoBiggest Stocks on Decline – NASDAQ – Nov. 17 (NASDAQ:CORI)
www.fxpips.com - November 17 at 10:32 AM
finance.yahoo.com logoAequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program (NASDAQ:CORI)
finance.yahoo.com - November 17 at 10:32 AM
finance.yahoo.com logo9:01 am Corium International enters service agreement w/ Aequus Pharma for the manufacturing of clinical trial materials for Aequus' transdermal doxylamine/pyridoxine long-acting patch, AQS1303 (NASDAQ:CORI)
finance.yahoo.com - November 17 at 10:32 AM
publicnow.com logoCorium to Report Fourth Quarter and Year-end Fiscal Year 2016 Financial Results on Monday, November 21, 2016 (NASDAQ:CORI)
www.publicnow.com - November 15 at 8:42 AM
publicnow.com logoCorium to Present at Dawson James Securities Growth Stock Conference (NASDAQ:CORI)
www.publicnow.com - October 13 at 4:19 PM
bizjournals.com logoThe tech behind Crest Whitestrips could help Alzheimer's patients (NASDAQ:CORI)
www.bizjournals.com - August 29 at 9:01 AM
finance.yahoo.com logoCorium International (CORI) Jumps: Stock Moves Up 6.9% (NASDAQ:CORI)
finance.yahoo.com - August 26 at 10:43 AM
bizjournals.com logoHow the tech behind Crest Whitestrips could help Alzheimer's patients (NASDAQ:CORI)
feeds.bizjournals.com - August 25 at 6:21 PM
News IconSigma Labs Announces Launch of PrintRite3D® INSPECT™ Software v1.3.2 and Upcoming Industry Events (NASDAQ:CORI)
www.econotimes.com - August 24 at 9:57 AM
publicnow.com logoCorium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex™ Memantine (NASDAQ:CORI)
www.publicnow.com - August 24 at 9:57 AM
capitalcube.com logoETF’s with exposure to Corium International, Inc. : August 23, 2016 (NASDAQ:CORI)
www.capitalcube.com - August 23 at 4:28 PM
finance.yahoo.com logoEdited Transcript of CORI earnings conference call or presentation 4-Aug-16 9:00pm GMT (NASDAQ:CORI)
finance.yahoo.com - August 19 at 3:26 PM

Social

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

Where is Corium International's stock going? Where will Corium International's stock price be in 2017?

6 brokers have issued twelve-month target prices for Corium International's stock. Their forecasts range from $8.00 to $16.00. On average, they anticipate Corium International's stock price to reach $11.17 in the next year.

When will Corium International announce their earnings?

Corium International is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

What are analysts saying about Corium International stock?

Here are some recent quotes from research analysts about Corium International stock:

  • According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (2/16/2017)

  • Jefferies Group LLC analysts commented, "CORI posted a slightly narrower than expected loss (-$10.4M vs -$11.2M JEF). Key pipeline product donepezil TD finished the 2nd of three stages of the pilot study and remains on track to start the pivotal Ph 3 study in 2H17. Partners P&G and AGRX continue to support the topline but a new partnership remains key for FY17 in order for mgt to remain credible and generate much needed non-dilutive financing." (2/15/2017)
  • Needham & Company LLC analysts commented, "CORI reported FY1Q17 financials and provided a development update for its Alzheimer's disease transdermal patch programs. The second treatment period of the ongoing pilot BE study for the donepezil patch recently completed and the first interim results are expected in March. The upcoming interim look could provide the initial derisking for the Corplex CNS patch program. CORI recently completed a $20MM equity raise that extends the cash runway into late-2017/ early-2018. We maintain our Buy rating and adjust our $PT to $10 (from $12) to reflect the new higher share count and expected volatility in revenues from partnered products." (2/14/2017)
  • FBR & Co analysts commented, "Corium reported below-consensus revenue and EPS after the market close on November 21. While EPS and revenues were disappointing in the quarter, we believe that investors should continue to focus on the company’s impressive CNS patch pipeline. Corium has received favorable written feedback from the FDA regarding its development of Corplex donepezil and Corplex memantine. The FDA has indicated that if Corium can demonstrate bioequivalence between its products and oral Aricept (donepezil) and oral Namenda XR (memantine) in bioequivalence (BE) studies, then it could submit a 505(b)(2) NDA without conducting additional clinical efficacy trials. We believe meaningful catalysts are ahead in 2017. Patient dosing started in September for a pilot study for Corplex donepezil in preparation for the pivotal BE trial in 2H17." (11/22/2016)

Who owns Corium International stock?

Corium International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wall Street Associates (0.94%). Company insiders that own Corium International stock include David Greenwood, Eric Bjerkholt and Peter D Staple.

Who sold Corium International stock? Who is selling Corium International stock?

Corium International's stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.

How do I buy Corium International stock?

Shares of Corium International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Corium International stock cost?

One share of Corium International stock can currently be purchased for approximately $3.84.

Corium International (NASDAQ:CORI) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)

Earnings History Chart

Earnings by Quarter for Corium International (NASDAQ:CORI)

Dividend History Chart

Dividend Payments by Quarter for Corium International (NASDAQ:CORI)

Last Updated on 2/19/2017 by MarketBeat.com Staff